Friday, August 23, 2013
Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it reached agreement with the FDA for two special protocol assessments for the company's pivotal Phase III program testing NAV5001 as an aid in the differential diagnosis of Parkinsonian syndromes from non-Parkinsonian tremor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.